Nxera Pharma Co., Ltd.

Caion has entered into a joint research agreement with FRONTEO regarding AI drug discovery. Additionally, CAPITA will record a special gain in the second quarter of the fiscal year ending March 2027 due to the sale of idle land. JMHD has revised down its consolidated earnings forecast for the fiscal year ending July 2026. Nexera has received a milestone payment of $86 million from Centessa based on progress in late-stage development. DWTi has decided on a domestic development plan for its glaucoma treatment agent H-1337. Blangista has seen additional share acquisition by SBINM LLC in connection with the strengthening of capital ties with SBI.

Nxera Pharma announced it will receive an $8.6 million milestone payment from Centessa Pharmaceuticals, a wholly-owned subsidiary of Eli Lilly and Company, following late-stage development progress in its selective orexin receptor 2 agonist portfolio. The payment, triggered under Nxera's research collaboration with Centessa, will be recognized as revenue in the third quarter of the fiscal year ending December 31, 2026. Lilly completed its acquisition of Centessa on June 24, 2026, gaining ownership of the OX2R agonist pipeline, which includes clinical-stage molecules for sleep-wake and neurological disorders. Nxera retains rights to future development and commercialization milestones and royalties from the programs. CEO Christopher Cargill expressed satisfaction with the clinical progress and the portfolio's potential to address major unmet needs.

In individual announcements released on the 26th, ABEJA resolved to establish a wholly-owned subsidiary in Singapore. Globing plans a significant profit increase and higher dividend for the fiscal year ending May 2027 (IFRS). Susmed's exclusive sales contract with Shionogi for its insomnia disorder app has ended. Nexera received a milestone payment of approximately 1.591 billion yen related to its partner Neurocrine's Phase 2 trial for cognitive impairment in Alzheimer's disease. Kasumigaseki Capital sold a property held for sale (Miami development land) for its first U.S. project, and Yamaha announced the partial sale of its shares in Yamaha Motor. Matsui Securities set its interim dividend for the fiscal year ending March 2027 at 28 yen (compared to 25 yen in the same period last year), and Medical Net resolved the material weakness in internal control over financial reporting that had been disclosed.

Nxera Pharma reported a net profit of JPY 1,591 million (US$10.1 million) for the six months ended 30 June 2026, reversing a net loss of JPY 3,137 million (US$21.1 million) in the prior corresponding period. Revenue totalled JPY 18,910 million (US$119.6 million), an increase of JPY 3,815 million (US$18.0 million) versus the prior corresponding period, driven by eight R&D milestone events in the current quarter compared with five a year earlier. Operating profit reached JPY 1,881 million (US$11.9 million) against an operating loss of JPY 2,756 million (US$18.5 million), while core operating profit surged to JPY 6,494 million (US$41.1 million) from JPY 364 million (US$2.5 million). The company highlighted progress across partnered programs, including milestone payments from Neurocrine Biosciences, AbbVie, and Centessa Pharmaceuticals, and noted that Lilly's acquisition of Centessa does not affect Nxera's rights to future milestone and royalty payments from the jointly created orexin receptor agonist pipeline.

Nxera Pharma has reached a fourth R&D milestone under its multi-target neurological disease collaboration with AbbVie, triggering a US$10 million payment. This milestone, the second achieved in 2026, relates to identifying validated hit molecules against a neurology target. Since the collaboration began in 2022, Nxera has received US$40 million in total milestone payments from AbbVie. Under the agreement, Nxera is eligible for up to US$1.2 billion in further option, development and commercial milestones, plus tiered royalties on sales.